Check patentability & draft patents in minutes with Patsnap Eureka AI!

Application of quinolizidine in preparing tumor treatment drugs

A technology of quinolizidine and tumor drugs is applied in the application field of quinolizidine alkaloids in the treatment of tumor drugs, and can solve the problems that the use has not yet been reported.

Inactive Publication Date: 2011-04-13
SHANTOU UNIV MEDICAL COLLEGE
View PDF3 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The use of aloperine-type, spartine-type and cytisine-type alkaloids in antitumor has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of quinolizidine in preparing tumor treatment drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1, using the conventional MTT method to carry out tumor suppression experiments, the methods and results are as follows:

[0022] MTT colorimetry is a method to detect cell survival and growth. This method has been widely used in large-scale antitumor drug screening, and it is characterized by high sensitivity and economy.

[0023] 0.5-2×105 of each of the above tumor cells was placed in a 96-well plate, and the preparation prepared by aloperine, spartine and cytisine was diluted to an experimental concentration, added to each tumor cell and treated for 48 hours. Three replicate wells were set up for each experimental group, the negative blank control wells were no drug added, and the positive drug control wells were sophoridine. The 5 mg / ml MTT solution stored at -20°C was dissolved at room temperature in the dark, and 10 μl of MTT solution was added to each well of a 96-well plate to mix well, and placed in a cell culture incubator for 4 hours. Add 100 μl of...

Embodiment 2

[0028] Example 2, inducing tumor cell autophagy:

[0029] It was shown in Example 1 that aloperine, spartine and cytisine can inhibit the proliferation of tumor cells. This example further verifies the anti-tumor activity of aloperine, spartine and cytisine.

[0030] After the drug preparations of each experimental group in Example 1 acted on the tumor cells for 18 hours, 0.5 ml of cells were taken and added to a 1.5 ml EP tube, and 5 μl of acridine orange was added, at 37° C. for 15 min. Add 0.5ml of PBS, centrifuge at 1500rpm at 4°C for 5min, discard the supernatant, collect the cells, and wash twice with 1ml of PBS. The cells were resuspended in 100 μl PBS, and the cells were observed under a fluorescent inverted microscope. It was found that the nuclei of the drug experimental group were red and autophagy occurred. This shows that the pharmaceutical preparation of the present invention can inhibit the proliferation of tumor cells by inducing the autophagy of the above-men...

Embodiment 3

[0031] Example 3, inducing tumor cell apoptosis:

[0032] PARP shearing and ladder DNA agarose gel electrophoresis, they are important indicators and characteristics of apoptosis. After the drug preparations of each experimental group continued to act on the above tumor cells for 48 hours in Example 2, PARP shearing and ladder DNA agarose gel electrophoresis were detected by conventional Western blotting, and it was found that the drug preparations continued to act on the above tumor cells for 48 hours Afterwards, PARP shearing and ladder-shaped DNA appeared, and the results showed that the pharmaceutical preparation of the present invention can finally induce the above-mentioned tumor cell apoptosis and achieve the effect of treating tumor cells.

[0033] Within the soluble concentration range of aloperine, spartine and cytisine, the IC50 of the action concentration is greater than 5-10 times more than tumor cells, indicating that aloperine, spartine and cytisine have less t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of quinolizidine comprising sparteine and cytisine extracted from Sophora plants in preparing tumor treatment drugs. The quinolizidine can be used for treating tumors including leukemia, lymphoma, cancer of the liver, cancer of the esophagus and lung cancer. A combined medical auxiliary material including therapy effective dose of active components: sparteine and cytisine is utilized to prepare clinically applied dosage forms like injections, tablets, capsules, release-controlled pills and the like.

Description

technical field [0001] The invention belongs to the field of pharmacy, and in particular relates to the application of quinolizidine alkaloids in drugs for treating tumors. technical background [0002] At present, tumor treatment mainly includes surgery, radiotherapy and chemotherapy, because the preferred treatment option for leukemia is still drug chemotherapy. Therefore, it is of great practical significance to develop natural anticancer drugs or lead compounds with high efficiency and low toxicity from plants. In the experimental example of the present invention, besides leukemia cells, tumor cells of digestive tract and respiratory tract cancers with high incidence in my country were also selected. [0003] The tumor cells selected in the present invention are all obtained from clinical tumor patients. For example, K562 cells are obtained from a 53-year-old female leukemia patient, HL60 cells are obtained from a 36-year-old female patient with acute promyelocytic leuk...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4748A61K31/439A61P35/00A61P35/02
Inventor 蒋纪恺刘小珊
Owner SHANTOU UNIV MEDICAL COLLEGE
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More